Literature DB >> 14671007

Current perspective on the pathogenesis of Graves' disease and ophthalmopathy.

Bellur S Prabhakar1, Rebecca S Bahn, Terry J Smith.   

Abstract

Graves' disease (GD) is a very common autoimmune disorder of the thyroid in which stimulatory antibodies bind to the thyrotropin receptor and activate glandular function, resulting in hyperthyroidism. In addition, some patients with GD develop localized manifestations including ophthalmopathy (GO) and dermopathy. Since the cloning of the receptor cDNA, significant progress has been made in understanding the structure-function relationship of the receptor, which has been discussed in a number of earlier reviews. In this paper, we have focused our discussion on studies related to the molecular mechanisms of the disease pathogenesis and the development of animal models for GD. It has become apparent that multiple factors contribute to the etiology of GD, including host genetic as well as environmental factors. Studies in experimental animals indicate that GD is a slowly progressing disease that involves activation and recruitment of thyrotropin receptor-specific T and B cells. This activation eventually results in the production of stimulatory antibodies that can cause hyperthyroidism. Similarly, significant new insights have been gained in our understanding of GO that occurs in a subset of patients with GD. As in GD, both environmental and genetic factors play important roles in the development of GO. Although a number of putative ocular autoantigens have been identified, their role in the pathogenesis of GO awaits confirmation. Extensive analyses of orbital tissues obtained from patients with GO have provided a clearer understanding of the roles of T and B cells, cytokines and chemokines, and various ocular tissues including ocular muscles and fibroblasts. Equally impressive is the progress made in understanding why connective tissues of the orbit and the skin in GO are singled out for activation and undergo extensive remodeling. Results to date indicate that fibroblasts can act as sentinel cells and initiate lymphocyte recruitment and tissue remodeling. Moreover, these fibroblasts can be readily activated by Ig in the sera of patients with GD, suggesting a central role for them in the pathogenesis. Collectively, recent studies have led to a better understanding of the pathogenesis of GD and GO and have opened up potential new avenues for developing novel treatments for GD and GO.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14671007     DOI: 10.1210/er.2002-0020

Source DB:  PubMed          Journal:  Endocr Rev        ISSN: 0163-769X            Impact factor:   19.871


  130 in total

1.  Time course of Graves' ophthalmopathy after total thyroidectomy alone or followed by radioiodine therapy: a 2-year longitudinal study.

Authors:  Annamaria De Bellis; Giovanni Conzo; Gilda Cennamo; Elena Pane; Giuseppe Bellastella; Caterina Colella; Assunta Dello Iacovo; Vanda Amoresano Paglionico; Antonio Agostino Sinisi; Jack R Wall; Antonio Bizzarro; Antonio Bellastella
Journal:  Endocrine       Date:  2011-11-16       Impact factor: 3.633

Review 2.  Recent developments in thyroid eye disease.

Authors:  Tom Cawood; Paul Moriarty; Donal O'Shea
Journal:  BMJ       Date:  2004-08-14

Review 3.  Potential role for bone marrow-derived fibrocytes in the orbital fibroblast heterogeneity associated with thyroid-associated ophthalmopathy.

Authors:  T J Smith
Journal:  Clin Exp Immunol       Date:  2010-08-19       Impact factor: 4.330

4.  Analysis of immune regulatory genes' copy number variants in Graves' disease.

Authors:  Amanda K Huber; Erlinda S Concepcion; Alisha Gandhi; Francesca Menconi; Eric P Smith; Mehdi Keddache; Yaron Tomer
Journal:  Thyroid       Date:  2010-11-08       Impact factor: 6.568

5.  Computer-Assisted Three-Dimensional Planning for Orbital Decompression.

Authors:  Nicholas Mahoney; Michael P Grant; Srinivas Murthy Susarla; Shannath Merbs
Journal:  Craniomaxillofac Trauma Reconstr       Date:  2014-11-14

Review 6.  Pharmacological treatments for thyroid eye disease.

Authors:  Sara P Modjtahedi; Bobeck S Modjtahedi; Ahmad M Mansury; Dinesh Selva; Raymond S Douglas; Robert A Goldberg; Igal Leibovitch
Journal:  Drugs       Date:  2006       Impact factor: 9.546

7.  Graves' ophthalmopathy: search for shared autoantigen(s) continues.

Authors:  L Bartalena
Journal:  J Endocrinol Invest       Date:  2005-05       Impact factor: 4.256

8.  Autoantibody against aldehyde dehydrogenase 2 could be a biomarker to monitor progression of Graves' orbitopathy.

Authors:  Kai-Chun Cheng; Yu-Jen Wu; Kai-Hung Cheng; Kai-Yuan Cheng; Kuo-Jen Chen; Wen-Chuan Wu; Po-Yen Lee; Cheng-Hsien Chang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-02-03       Impact factor: 3.117

9.  Poorly specific binding of thyroglobulin to orbital fibroblasts from patients with Graves' ophthalmopathy.

Authors:  S Lisi; R Botta; P Agretti; S Sellari-Franceschini; C Marcocci; A Pinchera; M Marinò
Journal:  J Endocrinol Invest       Date:  2005-05       Impact factor: 4.256

10.  Extraocular muscle susceptibility to myasthenia gravis: unique immunological environment?

Authors:  Jindrich Soltys; Bendi Gong; Henry J Kaminski; Yuefang Zhou; Linda L Kusner
Journal:  Ann N Y Acad Sci       Date:  2008       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.